Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear.<\/p>\n
OBJECTIVE\u00a0\u00a0\u00a0 To conduct a systematic review of the benefits and adverse events(AEs) of cannabinoids.<\/p>\n
DATA SOURCES\u00a0\u00a0\u00a0 Twenty-eight databases from inception to April2015.<\/p>\n
STUDY SELECTION\u00a0\u00a0\u00a0 Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation inHIV\/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety\u00a0 disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome.<\/p>\n
DATA EXTRACTION AND SYNTHESIS\u00a0\u00a0\u00a0 Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis.<\/p>\n
MAIN OUTCOMES AND MEASURES\u00a0\u00a0\u00a0\u00a0 Patient-relevant\/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs.<\/p>\n
RESULTS\u00a0\u00a0\u00a0 A total of 79 trials (6462participants) were included; 4 were judged at low risk of bias. Most trials\u00a0 showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47%vs20%; odds ratio[OR], 3.82[95%CI,1.55-9.42]; 3 trials),reduction in pain (37%vs31%;OR,1.41[95%CI,0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (ona0-10-point scale; weighted mean difference[WMD],\u22120.46[95%CI,\u22120.80to\u22120.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD,\u22120.36[95%CI,\u22120.69to\u22120.05];7trials). There was an\u00a0 increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs\u00a0 included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination.<\/p>\n
CONCLUSIONS AND RELEVANCE There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity.\u00a0 There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and\u00a0 vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increase d risk of short \u2013term AEs.<\/p>\n
Source: JAMA. 2015;313(24):2456-2473.doi:10.1001\/jama.2015.6358<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE\u00a0\u00a0\u00a0 To conduct a systematic review of the benefits and adverse events(AEs) of cannabinoids. DATA SOURCES\u00a0\u00a0\u00a0 Twenty-eight databases from inception to April2015. STUDY SELECTION\u00a0\u00a0\u00a0 Randomized clinical trials of cannabinoids for the following indications: […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30,60],"tags":[],"class_list":["post-11240","post","type-post","status-publish","format-standard","hentry","category-cannabis-marijuana","category-marijuana-and-medicine"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/11240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=11240"}],"version-history":[{"count":0,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/11240\/revisions"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=11240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=11240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=11240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}